IFP Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

IFP Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48	Hold	6	–	–	﹤0.01%	5024
2026 Q1	$35	Sell	6 -134	-96%	-$888	﹤0.01%	4876
2025 Q4	$1.1K	Buy	140 +120	+600%	+$944	﹤0.01%	4045
2025 Q3	$163	Sell	20 -60	-75%	-$399	﹤0.01%	4436
2025 Q2	$374	Buy	80 +54	+208%	+$247	﹤0.01%	4504
2025 Q1	$143	Hold	26	–	–	﹤0.01%	3765
2024 Q4	$88	Sell	26 -174	-87%	-$560	﹤0.01%	4080
2024 Q3	$570	Hold	200	–	–	﹤0.01%	3137
2024 Q2	$450	Hold	200	–	–	﹤0.01%	3098
2024 Q1	$442	Hold	200	–	–	﹤0.01%	2990
2023 Q4	$470	Hold	200	–	–	﹤0.01%	2881
2023 Q3	$372	Hold	200	–	–	﹤0.01%	3133
2023 Q2	$524	Hold	200	–	–	﹤0.01%	3190
2023 Q1	$472	Hold	200	–	–	﹤0.01%	3191
2022 Q4	$1K	Hold	200	–	–	﹤0.01%	4519
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	4708
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	4477
2022 Q1	$1K	Hold	200	–	–	﹤0.01%	4475
2021 Q4	$1K	Hold	200	–	–	﹤0.01%	3149
2021 Q3	$1K	Hold	200	–	–	﹤0.01%	3160
2021 Q2	$1K	Hold	200	–	–	﹤0.01%	2966
2021 Q1	$1K	Buy	+200	New	+$1.08K	﹤0.01%	2898
2018 Q4	–	Sell	-200	Closed	-$4K	–	3897
2018 Q3	$4K	Buy	+200	New	+$4.34K	﹤0.01%	3337

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

IFP Advisors's XERS Position: Q2 2026 in Review

IFP Advisors held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 6 shares worth $48. The position accounts for ﹤0.01% of the portfolio, ranked #5024.

IFP Advisors first reported a position in XERS in Q3 2018 and has held it in 23 quarters since. The position peaked at $4K in Q3 2018. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

IFP Advisors held 6 shares of Xeris Biopharma Holdings worth $48 as of Q2 2026.
IFP Advisors left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
Xeris Biopharma Holdings made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5024 holding.
IFP Advisors first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 23 quarters since.
IFP Advisors's Xeris Biopharma Holdings position peaked at $4K in Q3 2018.
240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.